Home Overview Press Room Blog Publications For Students about us
Search

Biotech & Pharma : Displaying 11-20 of 2484


US toughens rules for clinical-trial transparencyby Sara ReardonNature NewsSeptember 16th, 2016Under new HHS rule, researchers must register information on the design and results of trials within 21 days of enrolling their first patient-- regardless of outcome.
‘Motherless babies!’ How to create a tabloid science headline in five easy stepsby Gretchen VogelScience MagazineSeptember 14th, 2016A modest research report on cell division is translated as a hyperbolic breakthrough. Gretchen Vogel critiques the flaws of hype-driven, click-bait journalism.
Peru Fails to Deliver for Indigenous Womenby Shena CavalloopenDemocracySeptember 12th, 2016~300,000 poor, rural, and indigenous people forcibly sterilized according to state "quotas", but public prosecutor says no "crimes against humanity" charges for state actors.
When Evolution Fights Back Against Genetic Engineeringby Brooke BorelThe AtlanticSeptember 12th, 2016Gene drive raises irreversible threats to ecosystems and unpredictable consequences that cannot be vetted in controlled lab settings.
Seeking to Join Editas, Intellia, CRISPR Therapeutics Makes Long Awaited IPO Pushby Ben FidlerXconomySeptember 12th, 2016Emmanuelle Charpentier’s biotech firm files to go public (~$90M), joining other CRISPR-Cas9 co-discoverers: Jennifer Doudna (Intellia, $108M, 5/2016) and Feng Zhang (Editas, $98M, 2/2016).
DNA Dragnet: In Some Cities, Police Go From Stop-and-Frisk to Stop-and-Spitby Lauren KirchnerProPublicaSeptember 12th, 2016Private police databases expanding with DNA “voluntarily” collected from minors, without oversight or right to challenge.
Will Genetic Engineering Really Change Everything Forever? [Video Review]by Elliot HosmanSeptember 8th, 2016The hype surrounding CRISPR gene editing and a future of designer babies is on playback with a popular new video. Is its optimism justified? And who decides what’s inevitable?
Scandals Waiting to Happen: Institutional Conflicts of Interest at California Stem Cell Agencyby Pete ShanksSeptember 8th, 2016StemCells Inc., which has received tens of millions of dollars from the state-funded stem cell agency, paid its president a hefty sum when he joined its board a week after resigning his position.
Victory: Eggs-for-Research Bill Dies in California Legislatureby Emily Galpern, Biopolitical Times guest contributorSeptember 8th, 2016A bill that would have expanded the commercial markets for human eggs, putting women’s health at risk, never made it to the Governor’s desk.
Women Freeze Eggs to Gain Time to Find the Right Partners Study Findsby Nicola DavisThe Guardian September 7th, 2016With annual storage costs and low success rates, "fertility insurance" doesn't address root causes of delayed parenthood.
Displaying 11-20 of 2484  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760